The manufacturer of the Clindamycin active raw material also manufactures certain beta-lactam antibiotics and was found to have inadequate separation of these operations. While not confirmed, the possibility of cross-contamination exists. A Health Hazard Evaluation was conducted by both Health Canada and Apotex. Although the potential for serious adverse health consequences is remote, Apotex is voluntarily recalling this product as a precautionary measure due to the sensitizing nature of the potential cross-contaminants.
Retail Pharmacies, Wholesalers, Doctors, Hospitals in Canada including the following Provinces and Territories: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Nova Scotia, Northwest Territories, Nunavut, Ontario, Prince Edward Island, Quebec, Saskatchewan, Yukon. Batches were also manufactured and packaged for Pro-Doc Ltee. in Laval, Quebec. Some of the lots also went to International customers in United Arab Emirates, Antigua and Barbuda, Anguilla, Barbados, Bermuda, Bahamas, Belize, Grenada, Guyana, Iran, Jamaica, Saint Kitts And Nevis, Cayman Islands, Saint Lucia, Montserrat, Mexico, Palau, Saudi Arabia, Trinidad and Tobago, Virgin Islands, British.